Nauck, Michael A.

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

Riddle, M. C., Cefalu, W. T., Evans, P. H., Gerstein, H. C., Nauck, M. A., Oh, W. K., Rothberg, A. E., le Roux, C. W., Rubino, F., Schauer, P., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 92

Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis.

Huthmacher, J. A., Meier, J. J., & Nauck, M. A. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 91

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

Meier, J. J., Weyhe, D., Michaely, M., Senkal, M., Zumtobel, V., Nauck, M. A., Holst, J. J., Schmidt, W. E., & Gallwitz, B. (2004) · Critical Care Medicine

Hyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Treatment and Management

Cited by 89

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care

Diabetes Treatment and ManagementPancreatitis Pathology and Treatment

Cited by 87

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes

Nauck, M. A. (2004) · Hormone and Metabolic Research

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 72

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

Lingvay, I., Hansen, T., Macura, S., Marre, M., Nauck, M. A., de la Rosa, R., Woo, V., Yildirim, E., & Wilding, J. (2020) · BMJ Open Diabetes Research & Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 71

Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial.

Nauck, M. A., Muus Ghorbani, M. L., Kreiner, E., Saevereid, H. A., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2019) · Diabetes Care

Diabetes Treatment and ManagementGallbladder and Bile Duct Disorders

Cited by 69

GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family

Nauck, M. A., & Meier, J. J. (2019) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 65

Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes

Quast, D. R., Schenker, N., Menge, B. A., Nauck, M. A., Kapitza, C., & Meier, J. J. (2020) · Diabetes Care

Diabetes Treatment and ManagementGastrointestinal motility and disorders

Cited by 64

Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung.

Nauck, M. A., Reinecke, M., Perren, A., Frystyk, J., Berishvili, G., Zwimpfer, C., Figge, A. M., Flyvbjerg, A., Lankisch, P. G., Blum, W. F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism

Growth Hormone and Insulin-like Growth FactorsNeuroendocrine Tumor Research Advances

Cited by 63

Therapy of Type 2 Diabetes

Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 62

Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility

Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology

Diabetes Treatment and ManagementGastrointestinal motility and disorders

Cited by 61

α‐Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon‐like peptide 1 (7–36 amide) and to delay gastric emptying in Type 2 diabetic patients

Hücking, K., Kostic, Z., Pox, C., Ritzel, R., Holst, J. J., Schmiegel, W., & Nauck, M. A. (2005) · Diabetic Medicine

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 57

Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes

Nauck, M. A., Kahle, M., Baranov, O., Deacon, C. F., & Holst, J. J. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 44

The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications

Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 40

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity

Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 40

Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short‐ and long‐acting glucagon‐like peptide‐1 receptor agonists in type 2 diabetes

Quast, D. R., Nauck, M. A., Schenker, N., Menge, B. A., Kapitza, C., & Meier, J. J. (2021) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 39

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

Nauck, M. A., Frossard, J.-L., Barkin, J. S., Anglin, G., Hensley, I. E., Harper, K. D., & Milicevic, Z. (2017) · Diabetes Care

Diabetes Treatment and ManagementPancreatitis Pathology and Treatment

Cited by 36

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use: Results From the LEADER Trial

Verma, S., Leiter, L. A., Mazer, C. D., Bain, S. C., Buse, J., Marso, S., Nauck, M., Zinman, B., Bosch-Traberg, H., Rasmussen, S., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35

GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?

Nauck, M. A., & Meier, J. J. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 24

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 22

On the Effects of Glucagon-Like Peptide-1 on Blood Glucose Regulation in Normal and Diabetic Subjects

HOLST, J. J., TOFT-NIELSEN, M.-B., ØRSKOV, C., NAUCK, M., & WILLMS, B. (2006) · Annals of the New York Academy of Sciences

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 21

Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic β-cell area

Breuer, T. G. K., Menge, B. A., Banasch, M., Uhl, W., Tannapfel, A., Schmidt, W. E., Nauck, M. A., & Meier, J. J. (2010) · European Journal of Endocrinology

Pancreatic function and diabetesPancreatitis Pathology and Treatment

Cited by 20

Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo‐controlled clinical trials

Kang, Y. M., Punov, V., Lim, S., & Nauck, M. A. (2025) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 20